AUSPEX PHARMACEUTICALS, INC. (ASPX) financial statements (2021 and earlier)

Company profile

Business Address 3333 N. TORREY PINES COURT
LA JOLLA, CA 92037
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

Current Assets
Cash, cash equivalents, and short-term investments145
Cash and cash equivalents30
Short-term investments115
Prepaid expense0
Deferred costs0
Other undisclosed current assets5
Total current assets:151
Noncurrent Assets
Property, plant and equipment0
Other noncurrent assets0
Other undisclosed noncurrent assets0
Total noncurrent assets:0
Current Liabilities
Accounts payable and accrued liabilities14
Accounts payable7
Accrued liabilities5
Employee-related liabilities3
Other undisclosed current liabilities(3)
Total current liabilities:11
Noncurrent Liabilities
Long-term debt and lease obligation15
Long-term debt, excluding current maturities15
Liabilities, other than long-term debt0
Other liabilities0
Total noncurrent liabilities:15
Total liabilities:26
Stockholders' equity
Stockholders' equity attributable to parent121
Common stock0
Additional paid in capital246
Accumulated deficit(125)
Stockholders' equity attributable to noncontrolling interest4
Total stockholders' equity:125

Income statement (P&L) ($ in millions)

Operating expenses(50)
Operating loss:(50)
Nonoperating expense(9)
Interest and debt expense(3)
Loss before gain (loss) on sale of properties:(62)
Other undisclosed net income3
Net loss:(60)
Net loss attributable to noncontrolling interest(0)
Net loss available to common stockholders, diluted:(60)

Comprehensive Income ($ in millions)

Net loss:(60)
Comprehensive loss:(60)
Comprehensive loss, net of tax, attributable to noncontrolling interest(0)
Comprehensive loss, net of tax, attributable to parent:(60)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios


Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: